7 results on '"Amparo Ruiz Simón"'
Search Results
2. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
- Author
-
Noelia Martínez-Jañez, J. M. López-Vega, Encarna Adrover, Pedro Sánchez-Rovira, Maribel Casas, Juan de la Haba-Rodriguez, Sonia González, Eva Carrasco, Raquel Andrés, Manuel Ramos, Arrate Plazaola, Miguel Martin, Lourdes Calvo, Cesar Mendiola Fernandez, César A. Rodríguez, Álvaro Rodríguez-Lescure, Ana Isabel Ballesteros, Mireia Margeli Vila, Carlos Poblete Jara, Manuel Ruiz Borrego, Agustí Barnadas, Sonia Del Barco Berron, Montserrat Munoz-Mateu, MC Cámara, Nuria Ribelles, José Manuel Baena-Cañada, Amparo Ruiz Simón, Eduardo Martínez de Dueñas, Ana Santaballa, and Ana Lluch
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Breast Neoplasms ,Docetaxel ,Disease-Free Survival ,Drug Administration Schedule ,Capecitabine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Odds Ratio ,medicine ,Adjuvant therapy ,Humans ,Cyclophosphamide ,Aged ,Epirubicin ,Neoplasm Staging ,Chemotherapy ,business.industry ,Middle Aged ,medicine.disease ,Metastatic breast cancer ,Surgery ,Regimen ,Treatment Outcome ,Chemotherapy, Adjuvant ,Fluorouracil ,Lymphatic Metastasis ,Female ,Taxoids ,Lymph Nodes ,business ,Follow-Up Studies ,medicine.drug - Abstract
Purpose Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC. Patients and Methods Patients with operable node-positive BC (T1-3/N1-3) were eligible. After surgery, 1,384 patients were randomly assigned to receive epirubicin plus cyclophosphamide (EC; 90 and 600 mg/m2, respectively, × four cycles), followed by docetaxel (100 mg/m2 × four cycles; EC-T) or epirubicin plus docetaxel (ET; 90 and 75 mg/m2, respectively, × four cycles), followed by capecitabine (1,250 mg/m2 twice a day on days 1 to 14, × four cycles; ET-X); all regimens were given every 3 weeks. The primary end point was invasive disease-free survival. Secondary end points included safety (with an alopecia-specific study) and overall survival (OS). Results After a median follow-up of 6.6 years and 297 events, 86% of patients who received EC-T and 82% of those who received ET-X were invasive disease free at 5 years (hazard ratio, 1.30; 95% CI, 1.03 to 1.64; log-rank P = .03). The OS difference between arms was not statistically significant (hazard ratio, 1.13; 95% CI, 0.82 to 1.55; log-rank P = .46). The most frequent grade 3 to 4 adverse events in the EC-T versus ET-X arms were neutropenia (19% v 10%), with 7% febrile neutropenia across arms; fatigue (13% v 11%); diarrhea (3% v 11%); hand-foot syndrome (2% v 20%); mucositis (6% v 5%); vomiting (both, 5%); and myalgia (4.5% v 1%). Incomplete scalp hair recovery was more frequent in the EC-T than ET-X arm (30% v 14%), and patients who received EC-T wore wigs significantly longer than those who received ET-X (8.35 v 6.03 months). Conclusion Invasive disease-free survival, but not OS, was significantly superior for patients with node-positive early BC who received the adjuvant standard schedule EC-T than for those who received the experimental ET-X regimen. Toxicity profiles differed substantially across arms.
- Published
- 2015
3. Breast cancer during pregnancy
- Author
-
Amparo Ruiz Simón and Mª Concepción Sánchez Martínez
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Genes, BRCA2 ,Genes, BRCA1 ,Antineoplastic Agents ,Breast Neoplasms ,Vinblastine ,Breast cancer ,Pregnancy ,Internal medicine ,Epidemiology ,Epidemiology of cancer ,medicine ,Humans ,Anthracyclines ,skin and connective tissue diseases ,Fetus ,business.industry ,Obstetrics ,Incidence (epidemiology) ,Postpartum Period ,Pregnancy Outcome ,Cancer ,Vinorelbine ,Prognosis ,medicine.disease ,Breast Feeding ,Female ,Taxoids ,Breast carcinoma ,business ,Pregnancy Complications, Neoplastic - Abstract
As women in western countries delay childbearing, it has been hypothesized that the incidence of breast cancer diagnosed during pregnancy will increase. Breast carcinoma during pregnancy(BCP) put the health of the mother in conflict with that of the fetus. The aim is to give optimal treatment to the mother to maximise the chances of survival, whilst minimising the risk of harm of the fetus. Few breast surgeons or oncologist develop expertise in this area owing the rarity of the association. We report the epidemiology, pathology, clinical picture, therapeutic management and fetal outcome of pregnant women with breast cancer treated in our institution.
- Published
- 2010
4. Breast cancer in pregnancy: an institutional experience
- Author
-
Joaquín Gavilá Gregori, Carmen Herrero Vicent, Abraham Hernández Blanquisett, Amparo Ruiz Simón, Vicente Guillem Porta, and Angel Guerrero Zotano
- Subjects
Cancer Research ,medicine.medical_specialty ,Fetus ,Pregnancy ,Obstetrics ,business.industry ,Research ,Alternative medicine ,medicine.disease ,Breast cancer ,breast cancer ,Oncology ,medicine ,pregnancy ,postpartum ,delivery ,business - Abstract
Background Breast cancer is one of the most common cancers diagnosed during pregnancy. Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during pregnancy or within 12 months of delivery. Nowadays PABC can be safely diagnosed, staged, and treated during pregnancy with good outcomes for both the mother and the fetus. Recent studies suggest that prognosis of women diagnosed during postpartum seems to be worse. In order to gain a better understanding of the PABC, we reviewed our centre’s experience. Patients and methods We assessed the clinicopathological parameters, evolution, and outcome of patients treated in the Fundación Instituto Valenciano de Oncología of Valencia, Spain, from October 1990 to October 2013, and compared the results of patients diagnosed during pregnancy (group ‘A’) and patients diagnosed within one year of delivery (group ‘B’). Of 12,000 cases of breast cancer registered in our database, 35 cases of PABC were identified. We included 11 patients in group ‘A’ and 24 in group ‘B’. Results In our group the median age was 35 years (range 29–42), of which ten (28%) patients had family history (first grade) of breast cancer, four patients were BRCA 1 mutation carriers. Axillary node compromise was found in 19 patients (53.5%), 24 patients were stage II or III at diagnosis (68.5%), 22 (62.8%) were ER positive, and nine (25.7%) were HER-2 positive. In group A (n = 11), five patients diagnosed before 18th week decided that a therapeutic abortion be performed before treatment, two patients were treated during pregnancy, one with chemotherapy without treatment associated complications during delivery. Four women diagnosed after 28th week decided to delay the treatment until delivery. After a follow up of 172 months, the relapse free survival (RFS) was 69% at five years and 45% at ten years. Overall survival (OS) at five years was 90.8% and 74.2% at ten years for all patients. For group ‘A’ OS was higher with 90% at five years versus 80% in group ‘B’. The differences between the groups were not statistically significant p = 0.368. Conclusion In our experience, there is a higher OS in patients diagnosed during pregnancy suggesting a better prognosis for this group of women but the difference between the groups is not statistically significant. Our study is limited because of our small sample.
- Published
- 2015
5. Cuando una paciente con cáncer de mama metastásica luminal A es subsidiaria de quimioterapia en primera línea
- Author
-
Amparo Ruiz Simón, Angel Guerrero Zotano, Abraham Hernández Blanquisett, Carmen Herrero Vicent, Joaquín Gavilá Gregori, and Vicente Guillem Porta
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,business.industry ,030220 oncology & carcinogenesis ,Obstetrics and Gynecology ,Medicine ,Radiology, Nuclear Medicine and imaging ,Surgery ,business - Published
- 2016
6. SEOM clinical guidelines for the treatment of metastatic breast cancer
- Author
-
Álvaro Rodríguez Lescure, Isabel Álvarez López, Amparo Ruiz Simón, Dolores Isla Casado, Laura G. Estévez, Juan de la Haba Rodríguez, Lourdes Calvo Martínez, and Meritxell Bellet Ezquerra
- Subjects
Oncology ,Cancer Research ,Informed choice ,medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,Breast Neoplasms ,Breast cancer ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,Societies, Medical ,Chemotherapy ,business.industry ,Carcinoma ,Endocrine therapy ,Cancer ,Treatment options ,General Medicine ,medicine.disease ,Prognosis ,Metastatic breast cancer ,Spain ,Practice Guidelines as Topic ,Female ,business ,Algorithms - Abstract
Patients with metastatic breast cancer have a wide number of treatment options, including medical, surgical, and supportive care measures. Treatment decisions are based in predictive and prognostic factors and the informed choice of the patients. SEOM has elaborated these guidelines with evidence-based recommendations for the diagnostic work-up, treatment (chemotherapy, endocrine therapy and targeted therapies) and supportive care for the management of these patients.
- Published
- 2010
7. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
- Author
-
Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez-Lescure Á, Muñoz-Mateu M, González S, Margelí Vila M, Barnadas A, Ramos M, Del Barco Berron S, Jara C, Calvo L, Martínez-Jáñez N, Mendiola Fernández C, Rodríguez CA, Martínez de Dueñas E, Andrés R, Plazaola A, de la Haba-Rodríguez J, López-Vega JM, Adrover E, Ballesteros AI, Santaballa A, Sánchez-Rovira P, Baena-Cañada JM, Casas M, del Carmen Cámara M, Carrasco EM, and Lluch A
- Subjects
- Adult, Aged, Breast Neoplasms surgery, Capecitabine administration & dosage, Capecitabine adverse effects, Chemotherapy, Adjuvant, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Disease-Free Survival, Docetaxel, Drug Administration Schedule, Epirubicin administration & dosage, Epirubicin adverse effects, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Follow-Up Studies, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Staging, Odds Ratio, Taxoids administration & dosage, Taxoids adverse effects, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Lymph Nodes pathology
- Abstract
Purpose: Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC., Patients and Methods: Patients with operable node-positive BC (T1-3/N1-3) were eligible. After surgery, 1,384 patients were randomly assigned to receive epirubicin plus cyclophosphamide (EC; 90 and 600 mg/m(2), respectively, × four cycles), followed by docetaxel (100 mg/m(2) × four cycles; EC-T) or epirubicin plus docetaxel (ET; 90 and 75 mg/m(2), respectively, × four cycles), followed by capecitabine (1,250 mg/m(2) twice a day on days 1 to 14, × four cycles; ET-X); all regimens were given every 3 weeks. The primary end point was invasive disease-free survival. Secondary end points included safety (with an alopecia-specific study) and overall survival (OS)., Results: After a median follow-up of 6.6 years and 297 events, 86% of patients who received EC-T and 82% of those who received ET-X were invasive disease free at 5 years (hazard ratio, 1.30; 95% CI, 1.03 to 1.64; log-rank P = .03). The OS difference between arms was not statistically significant (hazard ratio, 1.13; 95% CI, 0.82 to 1.55; log-rank P = .46). The most frequent grade 3 to 4 adverse events in the EC-T versus ET-X arms were neutropenia (19% v 10%), with 7% febrile neutropenia across arms; fatigue (13% v 11%); diarrhea (3% v 11%); hand-foot syndrome (2% v 20%); mucositis (6% v 5%); vomiting (both, 5%); and myalgia (4.5% v 1%). Incomplete scalp hair recovery was more frequent in the EC-T than ET-X arm (30% v 14%), and patients who received EC-T wore wigs significantly longer than those who received ET-X (8.35 v 6.03 months)., Conclusion: Invasive disease-free survival, but not OS, was significantly superior for patients with node-positive early BC who received the adjuvant standard schedule EC-T than for those who received the experimental ET-X regimen. Toxicity profiles differed substantially across arms., (© 2015 by American Society of Clinical Oncology.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.